Tris(2-hydroxyethyl)-1,3,5-triazinetrione

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Remarks:

combined repeated dose and reproduction / developmental screening

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: according to information in OECD SIDS (2002)

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference 1

Reference Type:

publication

Title:

Unnamed

Year:

2001

Reference 2

Reference Type:

publication

Title:

Unnamed

Year:

2002

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

GLP compliance:

yes

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Tris(2-hydroxyethyl)-1,3,5-triazinetrione

EC Number:

212-660-9

EC Name:

Tris(2-hydroxyethyl)-1,3,5-triazinetrione

Cas Number:

839-90-7

Molecular formula:

C9H15N3O6

IUPAC Name:

tris(2-hydroxyethyl)-1,3,5-triazinane-2,4,6-trione

Details on test material:

- Identity: Tris(2-hydroxyethyl) isocyanurate (CAS: 839-90-7)
- Source: Nissan Chemical Industries, Ltd.; Lot No. 00915-1
- Purity: 99.0 %

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: 10 weeks old, both sexes
- Weight at study initiation: 335-364 g for males, 233-263 g for females

IN-LIFE DATES:
- Treatment period, Males: 49 days (14 days before mating and 35 days including 14 days for mating)
Treatment period, Females: 40-46 days (from 14 days prior to mating to day 3 of lactation.)
- Frequency of treatment: Daily
- Post treatment observation period: 1 day
- Duration of test, Males: 50 days
Duration of test, Females: From 14 days prior to mating to day 4 of lactation.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Remarks:

for injection

Analytical verification of doses or concentrations:

not specified

Duration of treatment / exposure:

- Treatment period, Males: 49 days (14 days before mating and 35 days including 14 days for mating)
- Treatment period, Females: 40-46 days (from 14 days prior to mating to day 3 of lactation.)

Frequency of treatment:

Daily

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

30 mg/kg bw/day (actual dose received)

Doses / concentrations 2

Dose / conc.:

100 mg/kg bw/day (actual dose received)

Doses / concentrations 3

Dose / conc.:

300 mg/kg bw/day (actual dose received)

Doses / concentrations 4

Dose / conc.:

1 000 mg/kg bw/day (actual dose received)

No. of animals per sex per dose:

12

Control animals:

yes, concurrent vehicle

Details on study design:

Post-treatment observation period: 1 day

Examinations

Observations and examinations performed and frequency:

Clinical observations performed and frequency:
- Clinical signs: Twice a day (just before and after administration)
- Body weight, Males: Twice a week
Body weight, Females: Twice a week for pre-mating and mating period, 0, 7, 14, 21st day of pregnancy and 0, 4th day of lactation period.
- Food consumption, Males: Twice a week for pre-mating period and after a mating period end.
Food consumption, Females: Twice a week for pre-mating period, 2, 9, 16, 21st day of pregnancy and 4th day of lactation period.

Hematological examinations (only for males):
Red blood cell count, white blood cell count, platelet count, hemoglobin concentration, hematocrit value, differential leukocyte counts,
protrombin time, activated partial thromboplastin time, fibrinogen, mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, reticulocyte count.

Blood chemical examinations (only for males):
Total protein, albumin, A/G ratio, blood urea nitrogen, creatinine, glucose, total cholesterol, total bilirubin, triglyceride, sodium, potassium,
chloride, calcium, inorganic phosphorus, alkaline phosphatase, AST, ALT, gamma-GTP.

Urinary examinations (only for males): Urinalysis was conducted just before the termination of treatment, and the following items were examined:
Volume, specific gravity, color, pH, protein, glucose, ketone body, bilirubin, occult blood, urobilinogen, urinary sediments.


This study was conducted to examine both repeated dose toxicity and  reproductive/developmental toxicity as an OECD screening combined study
(OECD 422 test guideline).  Therefore, hematological and blood chemical examinations, and urinalysis  for females were not performed.

Sacrifice and pathology:

GROSS PATHOLOGY: Yes, see below
WEIGHING OF ORGANS: Yes, see below
HISTOPATHOLOGY: Yes, see below

- Terminal sacrifice, Males: Killed on the day after the treatment period.
Terminal sacrifice, Females: Killed on day 4 of lactation. Females with no delivery were killed 4 days after the delivery expected date.
Females with no copulation were killed at the end of the mating period.

- Gross pathology: All rats received a full macroscopic examination  with tissue collection.

- Organs Weights: The following organs were weighed at necropsy:
Brain, pituitary, thyroids, heart, thymus, liver, spleen, adrenals, kidneys, testes, epididymides, ovaries.

- Histopathology: The following organs were microscopically observed for the control and 1000 mg/kg bw/day groups:
Brain, pituitary gland, thyroids, heart, thymus, liver, spleen, adrenals, kidneys, testes, epididymides, ovaries,
lung, trachea, pancreas, salivary glands, esophagus, stomach, duodenum, jejunum, ileum, caecum, rectum,
colon, lymph node, bladder, uterus, vagina, parathyroids, spinal cord, sciatic nerve, eyes, Harderian glands,
mammary gland,  bone marrow, seminal vesicle, prostate.
In addition, liver and spleen (male only) were also examined for the 30, 100 and 300 mg/kg bw/day groups.

Other examinations:

Reproductive and developmental toxicity parameters (addressed in separate endpoints).

Statistics:

Dunnett's test was used for numerical data.

Results and discussion

Results of examinations

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not examined

Haematological findings:

no effects observed

Description (incidence and severity):

examined only in males

Clinical biochemistry findings:

no effects observed

Description (incidence and severity):

examined only in males

Urinalysis findings:

no effects observed

Description (incidence and severity):

examined only in males

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

only in 2 females, no effect in males

Histopathological findings: neoplastic:

not examined

Details on results:

Histopathology
Males:  No treatment-related abnormality was observed.
Females:  Very slight (marginally positive) extramedullary hematopoiesis in the liver was noted in two female animals of the 1000 mg/kg bw/day group.

Effect levels

1

Key result

Dose descriptor:

NOEL

Effect level:

>= 1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: NOEL = highest dose tested. NOEL (instead of NOAEL stated by OECD SIDS) seems more appropriate, because OECD SIDS states: "No treatment related abnormality up to 1000 mg/kg bw/day in parental males."

2

Key result

Dose descriptor:

NOAEL

Effect level:

1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

female

Basis for effect level:

other: NOAEL = highest dose tested. Very slight extramedullary hematopoiesis in the liver in two parental females at 1000 mg/kg bw/day was statistically not significant, therefore not adverse.

Target system / organ toxicity

Key result

Critical effects observed:

no

Applicant's summary and conclusion

Conclusions:

There were no treatment related effects in male rats up to 1000 mg/kg bw/day. The only treatment related effect in females was very slight (marginally positive) extramedullary hematopoiesis in the liver in two female animals of the high dose group (1000 mg/kg bw/day). This finding was considered not to represent an adverse effect, because it did not differ statistically significantly from controls. Therefore, for treated male animals the no observed effect level (NOEL) was estimated to be 1000 mg/kg bw/day and for treated female animals the no observed adverse effect level (NOAEL) was estimated to be 1000 mg/kg bw/day.